satavaptan has been researched along with Hepatic Encephalopathy in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Córdoba, J; Ginès, P; Jepsen, P; Vilstrup, H; Watson, H; Wong, F | 1 |
| Andersen, PK; Jepsen, P; Vilstrup, H; Watson, H | 1 |
1 review(s) available for satavaptan and Hepatic Encephalopathy
| Article | Year |
|---|---|
Satavaptan treatment for ascites in patients with cirrhosis: a meta-analysis of effect on hepatic encephalopathy development.
Topics: Antidiuretic Hormone Receptor Antagonists; Ascites; Hepatic Encephalopathy; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Morpholines; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Research Design; Spiro Compounds; Survival Analysis | 2013 |
1 trial(s) available for satavaptan and Hepatic Encephalopathy
| Article | Year |
|---|---|
Diabetes as a risk factor for hepatic encephalopathy in cirrhosis patients.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Diabetes Mellitus; Dose-Response Relationship, Drug; Female; Follow-Up Studies; France; Hepatic Encephalopathy; Humans; Incidence; Liver Cirrhosis; Male; Middle Aged; Morpholines; Prognosis; Retrospective Studies; Risk Assessment; Risk Factors; Spiro Compounds; Survival Rate; Time Factors | 2015 |